Considering that Mcl-1 inhibitors have struggled to induce tumor regression in the clinic [59], and since the MAPK and PI3K/AKT pathways are active in aggressive thyroid cancer [70, 71] and can regulate Mcl-1 expression [60, 61], we questioned if targeting the PI3K/AKT axis is efficacious against Mcl-1 dependent mutant BRAF PTC. This evidence concerns the gene MCL1 and neoplasm.